Who are Hesperidin+Diosmin combination 1000's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Coumarin/troxerutin, Diosmin and Hesperidin Combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hesperidin-diosmin-combination-1000.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Hesperidin+Diosmin combination 1000 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hesperidin+Diosmin combination 1000 (Hesperidin+Diosmin combination 1000) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bioflavonoid combination. Area: Cardiovascular.

phase 3 Bioflavonoid combination Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Hesperidin+Diosmin combination 1000 (Hesperidin+Diosmin combination 1000) — Pirogov Russian National Research Medical University. Hesperidin and diosmin are bioflavonoids that improve venous tone and reduce capillary fragility by strengthening blood vessel walls and reducing inflammation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Hesperidin+Diosmin combination 1000 TARGET	Hesperidin+Diosmin combination 1000	Pirogov Russian National Research Medical University	phase 3	Bioflavonoid combination
Coumarin/troxerutin	Coumarin/troxerutin	Takeda	marketed	Venoprotective agent / Bioflavonoid combination
Diosmin and Hesperidin Combination	Diosmin and Hesperidin Combination	Ankara Etlik City Hospital	phase 3	Bioflavonoid combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bioflavonoid combination class)

Ankara Etlik City Hospital · 1 drug in this class
Pirogov Russian National Research Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hesperidin+Diosmin combination 1000 — Competitive Intelligence Brief. https://druglandscape.com/ci/hesperidin-diosmin-combination-1000. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab